Roche Venture Fund, Sofinnova Partners and AbbVie led a €35m Series A round in Enthera Pharmaceuticals, a biotech company developing disease-modifying biologics. "Having the Roche Venture Fund close out our Series A fundraising boosts our international investor syndicate and provides further validation of the work being done at Enthera. The considerable amount raised highlights both the strides that the Company is taking, and the advances that Italy has made within the industry," Giovanni Amabile, Enthera CEO.